Reduce dsRNA and optimize your IVT with our enhanced enzymes and high‑quality raw materials

WEBINAR

As regulatory expectations intensify, mRNA developers face stricter demands for impurity control, transparent documentation, and consistent raw‑material quality. Enzyme variability and elevated dsRNA reduce mRNA quality, impact safety and translation efficiency, and increase downstream purification burden.

In this insider session, we introduce our enhanced T7 RNA Polymerase and Inorganic Pyrophosphatase (IPP) Emprove^® Expert— designed to deliver higher transcription yields, significantly reduced dsRNA formation, and consistent performance across batches. Combined with our high‑quality raw materials portfolio and supported by comprehensive Emprove® Dossiers, these solutions help de‑risk development, strengthen regulatory readiness, and enable reliable, high‑purity mRNA production from early process development through scale‑up.

In this webinar, you will learn:

• Understand why selecting raw materials suitable for pharmaceutical use from the start is essential for reliable, high‑quality mRNA manufacturing.
• Learn why dsRNA formation remains a key challenge in IVT and how new technologies can help reduce manufacturing complexity and downstream burden
• Discover how our enhanced T7 RNA Polymerase Emprove^® Expert, and high‑quality raw materials improve transcription efficiency, reduce dsRNA, and deliver consistent performance.